Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARGIN-2
2022-002804-19Phase 2Active
- Sponsor
- University Medical Center Groningen
- Start
- Oct 2022
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab-IRDye800CW in breast cancer, sponsored by University Medical Center Groningen. Primary endpoint: Tumor-positive margin detection rate. Started Oct 2022; status: active.
02
Drugs
bevacizumab-IRDye800CW
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-002804-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002804-19.